Jörgen Ekström
Corporate Officer/Principal presso University of Gothenburg
Profilo
Jörgen Ekström was the founder of Calabar AB, which was founded in 1999, where he held the title of Director from 1999 to 2009.
Currently, he holds the title of Professor at the University of Gothenburg.
In the past, he held the title of Faculty Member at the University of Lund.
Posizioni attive di Jörgen Ekström
Società | Posizione | Inizio |
---|---|---|
University of Gothenburg | Corporate Officer/Principal | 24/01/2011 |
Precedenti posizioni note di Jörgen Ekström
Società | Posizione | Fine |
---|---|---|
University of Lund | Corporate Officer/Principal | - |
Calabar AB
Calabar AB Medical SpecialtiesHealth Technology Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound is currently undergoing Phase II repeated dose studies and Calabar is actively looking for partners to take the compound through phase III. For more information contact Business Development. The company is part of the Karolinska Development AB (publ) portfolio. | Fondatore | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Calabar AB
Calabar AB Medical SpecialtiesHealth Technology Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound is currently undergoing Phase II repeated dose studies and Calabar is actively looking for partners to take the compound through phase III. For more information contact Business Development. The company is part of the Karolinska Development AB (publ) portfolio. | Health Technology |
- Borsa valori
- Insiders
- Jörgen Ekström